MSLN and pancreatic neoplasm: To further investigate whether targeting MSLN with antibody (αMSLN) could enhance CD3+CD8+ T cell infiltration in pancreatic cancer, a mouse subcutaneous pancreatic cancer model based on Panc02 cells (mouse pancreatic ductal adenocarcinoma cell line that mimics the growth characteristics and immune microenvironment of human pancreatic tumors) was established and treated with αMSLN (Figure 1F).